{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T05:21:10Z","timestamp":1792214470386,"version":"4.4.0"},"reference-count":78,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100002386","name":"Cairo University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002386","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics and Research in Hepatology and Gastroenterology"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.clinre.2025.102543","type":"journal-article","created":{"date-parts":[[2025,1,29]],"date-time":"2025-01-29T08:11:16Z","timestamp":1738138276000},"page":"102543","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Efficacy and safety of dapagliflozin compared to pioglitazone in diabetic and non-diabetic patients with non-alcoholic steatohepatitis: A randomized clinical trial"],"prefix":"10.1016","volume":"49","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2568-1407","authenticated-orcid":false,"given":"Mona S.","family":"Abdel Monem","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdulmoneim","family":"Adel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maggie M.","family":"Abbassi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doaa H.","family":"Abdelaziz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Hassany","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maissa El","family":"Raziky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nirmeen A.","family":"Sabry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinre.2025.102543_bib0001","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.jhep.2024.04.031","article-title":"EASL\u2013EASD\u2013EASO clinical practice guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)","volume":"81","author":"Tacke","year":"2024","journal-title":"J Hepatol"},{"key":"10.1016\/j.clinre.2025.102543_bib0002","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1159\/000282080","article-title":"Epidemiology of non-alcoholic fatty liver disease","volume":"28","author":"Bellentani","year":"2010","journal-title":"Dig Dis"},{"key":"10.1016\/j.clinre.2025.102543_bib0003","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12902-022-00980-1","article-title":"Non-alcoholic fatty liver disease (NAFLD): a review of pathophysiology, clinical management and effects of weight loss","volume":"22","author":"Pouwels","year":"2022","journal-title":"BMC Endocr Disord"},{"key":"10.1016\/j.clinre.2025.102543_bib0004","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.gtc.2016.07.003","article-title":"Nonalcoholic fatty liver disease: pathophysiology and management","volume":"45","author":"Carr","year":"2016","journal-title":"Gastroenterol Clin North Am"},{"key":"10.1016\/j.clinre.2025.102543_bib0005","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1007\/s40273-022-01140-y","article-title":"The economic burden of non-alcoholic steatohepatitis: A systematic review","volume":"40","author":"Witkowski","year":"2022","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.clinre.2025.102543_bib0006","doi-asserted-by":"crossref","first-page":"01","DOI":"10.15226\/2374-6890\/3\/1\/00142","article-title":"Recent insights into treatment of non-alcoholic steatohepatitis","volume":"3","author":"Chiappini","year":"2016","journal-title":"J Endocrinol Diabetes"},{"key":"10.1016\/j.clinre.2025.102543_bib0007","doi-asserted-by":"crossref","first-page":"877","DOI":"10.3389\/fphar.2019.00877","article-title":"NAFLD and diabetes: two sides of the same coin? Rationale for gene-based personalized NAFLD treatment","volume":"10","author":"Xia","year":"2019","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.clinre.2025.102543_bib0008","unstructured":"FDA Approves first treatment for patients with liver scarring due to fatty liver disease | FDA n.d. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-treatment-patients-liver-scarring-due-fatty-liver-disease (accessed September 1, 2024)."},{"issue":"Suppl 1","key":"10.1016\/j.clinre.2025.102543_bib0009","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/liv.13302","article-title":"Therapies in non-alcoholic steatohepatitis (NASH)","volume":"37","author":"Oseini","year":"2017","journal-title":"Liver Int"},{"key":"10.1016\/j.clinre.2025.102543_bib0010","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1097\/HEP.0000000000000323","article-title":"AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease","volume":"77","author":"Rinella","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.clinre.2025.102543_bib0011","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1111\/jgh.13856","article-title":"The Asia-Pacific working party on non-alcoholic fatty liver disease guidelines 2017-Part 2: management and special groups","volume":"33","author":"Chitturi","year":"2018","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.clinre.2025.102543_bib0012","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.jhep.2015.11.004","article-title":"EASL\u2013EASD\u2013EASO Clinical practice guidelines for the management of non-alcoholic fatty liver disease","volume":"64","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.clinre.2025.102543_bib0013","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1056\/NEJMoa060326","article-title":"A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis","volume":"355","author":"Belfort","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinre.2025.102543_bib0014","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1056\/NEJMoa0907929","article-title":"Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis","volume":"362","author":"Sanyal","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinre.2025.102543_bib0015","article-title":"Response to pioglitazone in non-alcoholic fatty liver disease patients with vs. without type 2 diabetes: A meta-analysis of randomized controlled trials","volume":"14","author":"Wang","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.clinre.2025.102543_bib0016","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1177\/2042018814558243","article-title":"Dapagliflozin in patients with type 2 diabetes mellitus","volume":"6","author":"Filippatos","year":"2015","journal-title":"Ther Adv Endocrinol Metab"},{"key":"10.1016\/j.clinre.2025.102543_bib0017","doi-asserted-by":"crossref","DOI":"10.1016\/j.clinre.2022.101876","article-title":"Effects of dapagliflozin in patients with nonalcoholic fatty liver disease: A systematic review and meta-analysis of randomized controlled trials","volume":"46","author":"Sun","year":"2022","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"10.1016\/j.clinre.2025.102543_bib0018","doi-asserted-by":"crossref","DOI":"10.1016\/j.jdiacomp.2023.108558","article-title":"Effects of sodium-glucose co-transporter 2 inhibitors on liver fibrosis in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus: an updated meta-analysis of randomized controlled trials","volume":"37","author":"Jin","year":"2023","journal-title":"J Diabetes Complications"},{"key":"10.1016\/j.clinre.2025.102543_bib0019","doi-asserted-by":"crossref","first-page":"122","DOI":"10.36468\/pharmaceutical-sciences.spl.155","article-title":"Dapagliflozin therapy curative effect observation on nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus","volume":"82","author":"LIANG","year":"2020","journal-title":"Indian J Pharm Sci"},{"key":"10.1016\/j.clinre.2025.102543_bib0020","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.3390\/medicina59061136","article-title":"The effects of sodium-glucose cotransporter 2-inhibitors on steatosis and fibrosis in patients with non-alcoholic fatty liver disease or steatohepatitis and type 2 diabetes: A systematic review of randomized controlled trials","volume":"59","author":"Bica","year":"2023","journal-title":"Medicina (B Aires)"},{"key":"10.1016\/j.clinre.2025.102543_bib0021","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1007\/s00125-018-4675-2","article-title":"Effects of dapagliflozin and n-3 carboxylic acids on non-alcoholic fatty liver disease in people with type 2 diabetes: a double-blind randomised placebo-controlled study","volume":"61","author":"Eriksson","year":"2018","journal-title":"Diabetologia"},{"key":"10.1016\/j.clinre.2025.102543_bib0022","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1111\/dom.13520","article-title":"Evaluation of the effects of dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, on hepatic steatosis and fibrosis using transient elastography in patients with type 2 diabetes and non-alcoholic fatty liver disease","volume":"21","author":"Shimizu","year":"2019","journal-title":"Diabetes, Obes Metab"},{"key":"10.1016\/j.clinre.2025.102543_bib0023","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.curtheres.2017.07.002","article-title":"Effects of dapagliflozin on body composition and liver tests in patients with nonalcoholic steatohepatitis associated with type 2 diabetes mellitus: a prospective, open-label, uncontrolled study","volume":"87","author":"Tobita","year":"2017","journal-title":"Curr Ther Res Clin Exp"},{"key":"10.1016\/j.clinre.2025.102543_bib0024","doi-asserted-by":"crossref","first-page":"173","DOI":"10.3164\/jcbn.20-129","article-title":"Comparison of dapagliflozin and teneligliptin in nonalcoholic fatty liver disease patients without type 2 diabetes mellitus: a prospective randomized study","volume":"68","author":"Tobita","year":"2021","journal-title":"J Clin Biochem Nutr"},{"key":"10.1016\/j.clinre.2025.102543_bib0025","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.934136","article-title":"Dapagliflozin protects against nonalcoholic steatohepatitis in db\/db mice","volume":"13","author":"Qiao","year":"2022","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.clinre.2025.102543_bib0026","doi-asserted-by":"crossref","first-page":"190","DOI":"10.5603\/EP.a2023.0018","article-title":"Sodium glucose cotransporter-2-inhibitor dapagliflozin improves nonalcoholic fatty liver disease by ameliorating dipeptidyl-peptidase-4 protein expression in diabetic mice","volume":"74","author":"Zhao","year":"2023","journal-title":"Endokrynol Pol"},{"key":"10.1016\/j.clinre.2025.102543_bib0027","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0100777","article-title":"Long-term treatment with the sodium glucose cotransporter 2 inhibitor, dapagliflozin, ameliorates glucose homeostasis and diabetic nephropathy in db\/db mice","volume":"9","author":"Terami","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.clinre.2025.102543_bib0028","doi-asserted-by":"crossref","DOI":"10.2337\/db21-1170-P","article-title":"1170-P: Dapagliflozin, a sodium glucose cotransporter 2 inhibitor, attenuates the development of nonalcoholic steatohepatitis-associated hepatocellular carcinoma","volume":"70","author":"LEE","year":"2021","journal-title":"Diabetes"},{"key":"10.1016\/j.clinre.2025.102543_bib0029","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1001\/jama.2013.281053","article-title":"World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects","volume":"310","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.clinre.2025.102543_bib0030","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1053\/j.gastro.2021.10.051","article-title":"Expert panel review to compare FDA and EMA guidance on drug development and endpoints in nonalcoholic steatohepatitis","volume":"162","author":"Loomba","year":"2022","journal-title":"Gastroenterology"},{"key":"10.1016\/j.clinre.2025.102543_bib0031","first-page":"1","article-title":"Role of HbA1c in the diagnosis of patients with diabetes mellitus","volume":"6","author":"Zaidi","year":"2019","journal-title":"Era J Med Res"},{"key":"10.1016\/j.clinre.2025.102543_bib0032","unstructured":"Pioglitazone (marketed as Actos, Actoplus Met, Duetact, and Oseni) information | FDA n.d. https:\/\/www.fda.gov\/drugs\/postmarket-drug-safety-information-patients-and-providers\/pioglitazone-marketed-actos-actoplus-met-duetact-and-oseni-information (accessed March 29, 2023)."},{"key":"10.1016\/j.clinre.2025.102543_bib0033","unstructured":"FARXIGA\u00ae (dapagliflozin) tablets, for oral use n.d. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/202293s018lbl.pdf (accessed April 24, 2023)."},{"key":"10.1016\/j.clinre.2025.102543_bib0034","doi-asserted-by":"crossref","first-page":"339","DOI":"10.2165\/00003088-197601050-00002","article-title":"Drug metabolism in thyroid disease","volume":"1","author":"Eichelbaum","year":"1976","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.clinre.2025.102543_bib0035","unstructured":"Dapagliflozin (Forxiga): no longer authorised for treatment of type 1 diabetes mellitus - GOV.UK n.d. https:\/\/www.gov.uk\/drug-safety-update\/dapagliflozin-forxiga-no-longer-authorised-for-treatment-of-type-1-diabetes-mellitus (accessed October 27, 2023)."},{"key":"10.1016\/j.clinre.2025.102543_bib0036","unstructured":"Urbaniak GC, Plous S. Research randomizer (Version 4.0) n.d. https:\/\/www.randomizer.org\/(accessed July 11, 2022)."},{"key":"10.1016\/j.clinre.2025.102543_bib0037","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13643-019-1200-8","article-title":"Diabetes drugs for nonalcoholic fatty liver disease: a systematic review","volume":"8","author":"Blazina","year":"2019","journal-title":"Syst Rev"},{"key":"10.1016\/j.clinre.2025.102543_bib0038","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2022.109791","article-title":"Dapagliflozin for nonalcoholic fatty liver disease: a systematic review and meta-analysis","volume":"185","author":"He","year":"2022","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.clinre.2025.102543_bib0039","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1002\/cld.918","article-title":"Nutrition management strategies for nonalcoholic fatty liver disease: treatment and prevention","volume":"15","author":"Miller","year":"2020","journal-title":"Clin Liver Dis"},{"key":"10.1016\/j.clinre.2025.102543_bib0040","doi-asserted-by":"crossref","first-page":"703","DOI":"10.4103\/1119-3077.163288","article-title":"Nonalcoholic fatty liver disease: synopsis of current developments","volume":"18","author":"Onyekwere","year":"2015","journal-title":"Niger J Clin Pract"},{"key":"10.1016\/j.clinre.2025.102543_bib0041","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.cld.2015.10.011","article-title":"Histology of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis in adults and children","volume":"20","author":"Kleiner","year":"2016","journal-title":"Clin Liver Dis"},{"key":"10.1016\/j.clinre.2025.102543_bib0042","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S0197-2456(98)00005-1","article-title":"Drug compliance in therapeutic trials: a review","volume":"19","author":"Boudes","year":"1998","journal-title":"Control Clin Trials"},{"key":"10.1016\/j.clinre.2025.102543_bib0043","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1136\/gut.45.2.295","article-title":"Development of a disease specific questionnaire to measure health related quality of life in patients with chronic liver disease","volume":"45","author":"Younossi","year":"1999","journal-title":"Gut"},{"key":"10.1016\/j.clinre.2025.102543_bib0044","first-page":"35","article-title":"Quality of life of patients with chronic liver disease","volume":"4","author":"El-Gilany","year":"2015","journal-title":"IOSR J Nurs Heal Sci"},{"key":"10.1016\/j.clinre.2025.102543_bib0045","series-title":"Understanding your liver elastography (FibroScan\u00ae) results","year":"2022"},{"key":"10.1016\/j.clinre.2025.102543_bib0046","doi-asserted-by":"crossref","DOI":"10.1016\/j.cct.2019.06.017","article-title":"REGENERATE: design of a pivotal, randomised, phase 3 study evaluating the safety and efficacy of obeticholic acid in patients with fibrosis due to nonalcoholic steatohepatitis","volume":"84","author":"Ratziu","year":"2019","journal-title":"Contemp Clin Trials"},{"key":"10.1016\/j.clinre.2025.102543_bib0047","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.2337\/dc21-2049","article-title":"Comparison of tofogliflozin and glimepiride effects on nonalcoholic fatty liver disease in participants with type 2 diabetes: A randomized, 48-week, open-label, active-controlled trial","volume":"45","author":"Takeshita","year":"2022","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clinre.2025.102543_bib0048","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.jhep.2020.03.039","article-title":"A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement","volume":"73","author":"Eslam","year":"2020","journal-title":"J Hepatol"},{"key":"10.1016\/j.clinre.2025.102543_bib0049","unstructured":"From NAFLD to MAFLD: navigating the future of fatty liver treatment n.d. https:\/\/www.nature.com\/articles\/d43747-023-00038-8 (accessed September 1, 2024)."},{"key":"10.1016\/j.clinre.2025.102543_bib0050","doi-asserted-by":"crossref","DOI":"10.1177\/20420188221145549","article-title":"MAFLD: a multisystem disease","volume":"14","author":"Pipitone","year":"2023","journal-title":"Ther Adv Endocrinol Metab"},{"key":"10.1016\/j.clinre.2025.102543_bib0051","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.934136","article-title":"Dapagliflozin protects against nonalcoholic steatohepatitis in db\/db mice","volume":"13","author":"Qiao","year":"2022","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.clinre.2025.102543_bib0052","doi-asserted-by":"crossref","first-page":"305","DOI":"10.7326\/M15-1774","article-title":"Long-term pioglitazone treatment for patients with nonalcoholic steatohepatitis and prediabetes or type 2 diabetes mellitus: a randomized trial","volume":"165","author":"Cusi","year":"2016","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.clinre.2025.102543_bib0053","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1053\/j.gastro.2008.06.047","article-title":"Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis","volume":"135","author":"Aithal","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1016\/j.clinre.2025.102543_bib0054","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1002\/hep4.1696","article-title":"Ipragliflozin improves the hepatic outcomes of patients with diabetes with NAFLD","volume":"6","author":"Takahashi","year":"2022","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.clinre.2025.102543_bib0055","doi-asserted-by":"crossref","first-page":"259","DOI":"10.3390\/jcm9010259","article-title":"Ipragliflozin additively ameliorates non-alcoholic fatty liver disease in patients with type 2 diabetes controlled with metformin and pioglitazone: a 24-week randomized controlled trial","volume":"9","author":"Han","year":"2020","journal-title":"J Clin Med"},{"key":"10.1016\/j.clinre.2025.102543_bib0056","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1111\/jdi.13279","article-title":"Comparison of the effects of three kinds of glucose-lowering drugs on non-alcoholic fatty liver disease in patients with type 2 diabetes: a randomized, open-label, three-arm, active control study","volume":"11","author":"Kinoshita","year":"2020","journal-title":"J Diabetes Investig"},{"key":"10.1016\/j.clinre.2025.102543_bib0057","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1111\/jdi.13457","article-title":"Favorable effect of sodium\u2013glucose cotransporter 2 inhibitor, dapagliflozin, on non-alcoholic fatty liver disease compared with pioglitazone","volume":"12","author":"Cho","year":"2021","journal-title":"J Diabetes Investig"},{"key":"10.1016\/j.clinre.2025.102543_bib0058","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1111\/liv.13481","article-title":"Concomitant screening for liver fibrosis and steatosis in French type 2 diabetic patients using Fibroscan","volume":"37","author":"Roulot","year":"2017","journal-title":"Liver Int"},{"key":"10.1016\/j.clinre.2025.102543_bib0059","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.jceh.2019.06.003","article-title":"Antidiabetic drugs and statins in nonalcoholic fatty liver disease","volume":"9","author":"Kothari","year":"2019","journal-title":"J Clin Exp Hepatol"},{"key":"10.1016\/j.clinre.2025.102543_bib0060","doi-asserted-by":"crossref","DOI":"10.1136\/bmjdrc-2020-001990","article-title":"Comparing the effects of tofogliflozin and pioglitazone in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus (ToPiND study): a randomized prospective open-label controlled trial","volume":"9","author":"Yoneda","year":"2021","journal-title":"BMJ Open Diabetes Res Care"},{"key":"10.1016\/j.clinre.2025.102543_bib0061","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1111\/j.1572-0241.2005.41583.x","article-title":"A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease","volume":"100","author":"Bugianesi","year":"2005","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.clinre.2025.102543_bib0062","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1038\/nrgastro.2013.138","article-title":"NAFLD: predictive value of ALT levels for NASH and advanced fibrosis","volume":"10","author":"Torres","year":"2013","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.clinre.2025.102543_bib0063","unstructured":"Pioglitazone. National institute of diabetes and digestive and kidney diseases; 2012."},{"key":"10.1016\/j.clinre.2025.102543_bib0064","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.635556","article-title":"Effect of SGLT2 inhibitors on type 2 diabetes mellitus with non-alcoholic fatty liver disease: a meta-analysis of randomized controlled trials","volume":"12","author":"Wei","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.clinre.2025.102543_bib0065","article-title":"Non alcoholic fatty liver disease and degree of steatosis in diabetic and non- diabetic patients","volume":"19","author":"Khafagy","year":"2020","journal-title":"Obes Med"},{"key":"10.1016\/j.clinre.2025.102543_bib0066","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40246-024-00582-z","article-title":"Gene expression analysis reveals diabetes-related gene signatures","volume":"18","author":"Farrim","year":"2024","journal-title":"Hum Genomics"},{"key":"10.1016\/j.clinre.2025.102543_bib0067","doi-asserted-by":"crossref","first-page":"20","DOI":"10.2337\/dsi23-0013","article-title":"Role of insulin resistance in the development of nonalcoholic fatty liver disease in people with type 2 diabetes: from bench to patient care","volume":"37","author":"Nogueira","year":"2024","journal-title":"Diabetes Spectr"},{"key":"10.1016\/j.clinre.2025.102543_bib0068","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbadis.2020.166044","article-title":"Diabetic fibrosis","volume":"1867","author":"Tuleta","year":"2021","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"10.1016\/j.clinre.2025.102543_bib0069","doi-asserted-by":"crossref","first-page":"272","DOI":"10.3390\/life14020272","article-title":"NAFLD fibrosis progression and type 2 diabetes: the hepatic\u2013metabolic interplay","volume":"14","author":"Cernea","year":"2024","journal-title":"Life"},{"key":"10.1016\/j.clinre.2025.102543_bib0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhepr.2022.100525","article-title":"The burden of non-alcoholic steatohepatitis: a systematic review of health-related quality of life and patient-reported outcomes","volume":"4","author":"Younossi","year":"2022","journal-title":"JHEP Reports"},{"key":"10.1016\/j.clinre.2025.102543_bib0071","first-page":"690","article-title":"Enhancing quality of life in the patients suffering from non-alcoholic fatty liver disease through standard treatment interventions","volume":"30","author":"Asif","year":"2023","journal-title":"J Popul Ther Clin Pharmacol"},{"key":"10.1016\/j.clinre.2025.102543_bib0072","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1007\/s40265-021-01573-3","article-title":"A role for SGLT-2 inhibitors in treating non-diabetic chronic kidney disease","volume":"81","author":"Del Vecchio","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.clinre.2025.102543_bib0073","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.nefro.2023.11.001","article-title":"Effect of SGLT2 inhibitors on anemia and their possible clinical implications","volume":"44","author":"Cases","year":"2024","journal-title":"Nefrolog\u00eda"},{"key":"10.1016\/j.clinre.2025.102543_bib0074","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1007\/BF00280883","article-title":"Homeostasis model assessment: insulin resistance and ?-cell function from fasting plasma glucose and insulin concentrations in man","volume":"28","author":"Matthews","year":"1985","journal-title":"Diabetologia"},{"key":"10.1016\/j.clinre.2025.102543_bib0075","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1093\/clinchem\/18.6.499","article-title":"Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge","volume":"18","author":"Friedewald","year":"1972","journal-title":"Clin Chem"},{"key":"10.1016\/j.clinre.2025.102543_bib0076","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.3748\/wjg.v19.i8.1219","article-title":"NAFLD fibrosis score: A prognostic predictor for mortality and liver complications among NAFLD patients","volume":"19","author":"Treeprasertsuk","year":"2013","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.clinre.2025.102543_bib0077","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1002\/hep.21496","article-title":"The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD","volume":"45","author":"Angulo","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.clinre.2025.102543_bib0078","article-title":"The diagnostic value of the FIB-4 index for staging hepatitis B-related fibrosis: a meta-analysis","volume":"9","author":"Li","year":"2014","journal-title":"PLoS One"}],"container-title":["Clinics and Research in Hepatology and Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2210740125000233?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2210740125000233?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,24]],"date-time":"2025-05-24T23:05:12Z","timestamp":1748127912000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2210740125000233"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":78,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["S2210740125000233"],"URL":"https:\/\/doi.org\/10.1016\/j.clinre.2025.102543","relation":{},"ISSN":["2210-7401"],"issn-type":[{"value":"2210-7401","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of dapagliflozin compared to pioglitazone in diabetic and non-diabetic patients with non-alcoholic steatohepatitis: A randomized clinical trial","name":"articletitle","label":"Article Title"},{"value":"Clinics and Research in Hepatology and Gastroenterology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinre.2025.102543","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102543"}}